Israeli company Navotek Medical Ltd., which is backed by a Cleveland-based venture firm, received U.S. regulatory clearance for its radiation therapy monitoring system.
Navotek’s RealEye system obtained 510(k) clearance from the Food & Drug Administration for the treatment of patients with prostate cancer. The company says the system helps doctors more precisely monitor the delivery of radiation therapy, which helps reduce the risk of collateral damage to healthy tissue.
Navotek has already received regulatory clearance to commercialize the RealEye system in the European Union.